Gates Foundation announces $83.5M antimalaria funds
The Bill & Melinda Gates Foundation has announced a new commitment of $83.5 million in grants to counter malaria, in advance of a meeting at the White House, Washington DC, USA, to discuss action on the disease.
The Foundation states that the funds will be employed to "speed research on vaccines and other new prevention methods," among other measures, such as bednets and treatments. In a statement, Melinda Gates, co-chairperson of the Foundation, said: "the world is finally waking up to the malaria catastrophe. It's time to close the gap in funding, accelerate research and work together in a more strategic way to strengthen the global malaria fight."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze